Market capitalization | $516.44m |
Enterprise Value | $503.76m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.48 |
P/S ratio (TTM) P/S ratio | 2.55 |
P/B ratio (TTM) P/B ratio | 4.92 |
Revenue growth (TTM) Revenue growth | 16.14% |
Revenue (TTM) Revenue | $202.86m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Treace Medical Concepts Inc forecast:
6 Analysts have issued a Treace Medical Concepts Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 203 203 |
16%
16%
|
|
Gross Profit | 164 164 |
16%
16%
|
|
EBITDA | -54 -54 |
30%
30%
|
EBIT (Operating Income) EBIT | -62 -62 |
29%
29%
|
Net Profit | -62 -62 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
Head office | United States |
CEO | John Treace |
Employees | 516 |
Founded | 2013 |
Website | www.treace.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.